-
- Monotherapy
- Combination therapy
-
- Melanoma
- Non‑Small Cell Lung Cancer (NSCLC)
- Malignant Pleural Mesothelioma (MPM)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Classical Hodgkin Lymphoma (cHL)
- Primary Mediastinal Large B‑Cell Lymphoma (PMBCL)
- Urothelial Cancer
- Microsatellite Instability‑High/Mismatch Repair Deficient (MSI‑H/dMMR) Solid Tumors
- MSI‑H/dMMR Colorectal Cancer (CRC)
- Gastric Adenocarcinoma/Gastroesophageal Junction (GEJ) Cancer
- Esophageal/GEJ Carcinoma
- Cervical Cancer
- Hepatocellular Carcinoma (HCC)
- Biliary Tract Cancer (BTC)
- Merkel Cell Carcinoma (MCC)
- Renal Cell Carcinoma (RCC)
- Endometrial Carcinoma
- Tumor Mutational Burden‑High (TMB‑H) Solid Tumors
- Cutaneous Squamous Cell Carcinoma (cSCC)
- Triple‑Negative Breast Cancer (TNBC)
-
- Fixed-Dose (Adult)
- 200 mg every 3 weeks
- 400 mg every 6 weeks
- Weight-Based (Pediatric)
- 2 mg/kg (up to 200 mg) every 3 weeks
-
-
-
- Hospital pharmacies
- Specialty/Retail pharmacies
- Online pharmacies
-
- Hospitals
- Academic and Research Cancer Centers
- Specialty Cancer Clinics
- Ambulatory Infusion Centers
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa